Your browser doesn't support javascript.
loading
Biopsy and Margins Optimize Outcomes after Thermal Ablation of Colorectal Liver Metastases.
Vasiniotis Kamarinos, Nikiforos; Vakiani, Efsevia; Gonen, Mithat; Kemeny, Nancy E; Sigel, Carlie; Saltz, Leonard B; Brown, Karen T; Covey, Anne M; Erinjeri, Joseph P; Brody, Lynn A; Ziv, Etay; Yarmohammadi, Hooman; Kunin, Henry; Barlas, Afsar; Petre, Elena N; Kingham, Peter T; D'Angelica, Michael I; Manova-Todorova, Katia; Solomon, Stephen B; Sofocleous, Constantinos T.
Afiliação
  • Vasiniotis Kamarinos N; Interventional Oncology/IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Vakiani E; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Gonen M; Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Kemeny NE; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Sigel C; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Saltz LB; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Brown KT; Interventional Oncology/IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Covey AM; Interventional Oncology/IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Erinjeri JP; Interventional Oncology/IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Brody LA; Interventional Oncology/IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Ziv E; Interventional Oncology/IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Yarmohammadi H; Interventional Oncology/IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Kunin H; Interventional Oncology/IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Barlas A; Molecular Cytology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Petre EN; Interventional Oncology/IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Kingham PT; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • D'Angelica MI; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Manova-Todorova K; Molecular Cytology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Solomon SB; Interventional Oncology/IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Sofocleous CT; Interventional Oncology/IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Cancers (Basel) ; 14(3)2022 Jan 29.
Article em En | MEDLINE | ID: mdl-35158963
ABSTRACT

BACKGROUND:

Thermal ablation is a definitive local treatment for selected colorectal liver metastases (CLM) that can be ablated with adequate margins. A critical limitation has been local tumor progression (LTP).

METHODS:

This prospective, single-group, phase 2 study enrolled patients with CLM < 5 cm in maximum diameter, at a tertiary cancer center between November 2009 and February 2019. Biopsy of the ablation zone center and margin was performed immediately after ablation. Viable tumor in tissue biopsy and ablation margins < 5 mm were assessed as predictors of 12-month LTP.

RESULTS:

We enrolled 107 patients with 182 CLMs. Mean tumor size was 2.0 (range, 0.6-4.6) cm. Microwave ablation was used in 51% and radiofrequency ablation in 49% of tumors. The 12- and 24-month cumulative incidence of LTP was 22% (95% confidence interval [CI] 17, 29) and 29% (95% CI 23, 36), respectively. LTP at 12 months was 7% (95% CI 3, 14) for the biopsy tumor-negative ablation zone with margins ≥ 5 mm vs. 63% (95% CI 35, 85) for the biopsy-positive ablation zone with margins < 5 mm (p < 0.001).

CONCLUSIONS:

Biopsy-proven complete tumor ablation with margins of at least 5 mm achieves optimal local tumor control for CLM, regardless of the ablation modality used.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos